News
6h
The Times of Israel on MSNZelig Eshhar, leading cancer researcher and immunologist, dies at 84Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for ...
While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.
A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...
A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the ...
A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...
2d
News-Medical.Net on MSNLeukemia-on-a-chip offers breakthrough in personalized cancer treatmentA team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could ...
2d
Interesting Engineering on MSNCredit-card-sized chip reveals how immune cells hunt and kill cancer in real timeEngineered chip mimics bone marrow and immune system, offering a faster, tailored path for cancer immunotherapy.
During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $69.0, a high ...
A Martin County family with a child fighting rare cancer is getting help from the community to get treatment abroad.
Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.
Multiple myeloma begins when abnormal cells multiply and grow uncontrollably in a person’s bone marrow, crowding out healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results